Issue Date: October 17, 2016
Helsinn launches venture fund
The Swiss drug firm Helsinn has started a $50 million venture capital fund to invest in drug, device, and food start-ups. The fund will support firms with early-stage technologies for cancer therapeutics, diagnostics, and supportive care; metabolic and gastrointestinal disorders; and dermatology conditions. Helsinn will invest in 10 to 15 firms, providing scientific and clinical strategy guidance, along with operational and board support. So far, the fund has invested in firms including MEI Pharma, OncoResponse, and QuantuMDx.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society